title: Purinergic signaling, dyslipidemia and inflammatory disease.
abstract: Metabolic syndrome is a compound obesity disorder, wherein the abnormal metabolism of glucose and lipid is associated with the development of chronic inflammatory diseases. The prevalence of this disease is increasing in the developed world, but the causative linkage between these metabolic disorders has remained obscure. Metabolic disease may be associated with chronic nucleotide secretion, purinergic signaling and activation of inflammatory pathways. Purinergic signaling has been implicated in impaired glucose metabolism and inflammatory disease and may contribute to dyslipidemia. Our research shows that purinergic signaling disrupts hepatic lipoprotein metabolism by blocking insulin receptor signaling and by activating cellular autophagic pathways. Chronic stimulation of purinergic signaling may therefore be causative to glucose and lipid metabolic disorders and associated with the development of cardiovascular disease.
authors.affiliation: Atherosclerosis, Genetics and Cell Biology Group, University of Ottawa Heart Institute, Ottawa, ON, K1Y 4W7, Canada. dsparks@ottawaheart.ca
authors.forename: Daniel L
authors.initials: DL
authors.lastname: Sparks
authors.forename: Cynthia
authors.initials: C
authors.lastname: Chatterjee
mesh_terms: D001343:Autophagy; D006801:Humans; D007249:Inflammation / Q000378:metabolism; D018836:Inflammation Mediators / Q000378:metabolism*; D008074:Lipoproteins / Q000378:metabolism; D008659:Metabolic Diseases / Q000276:immunology / Q000378:metabolism / Q000473:pathology; D009711:Nucleotides / Q000378:metabolism*; D059748:Proteolysis; D058905:Purinergic Agents / Q000378:metabolism*; D015398:Signal Transduction
chemical_list: D018836:Inflammation Mediators; D008074:Lipoproteins; D009711:Nucleotides; D058905:Purinergic Agents